CDK1可能通过AKT激活和免疫调节促进乳腺癌的进展
Huanhong Zeng1, Minxue Zhuang1, Bochuan Liang2
1Shengli Clinical Medical College of Fujian Medical University, Department of Breast Surgery, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou University, Fuzhou, China.
Frontiers in oncology
|November 24, 2025
概括
循环素依赖激酶1 (CDK1) 在乳腺癌中过度表达,与预后不佳和免疫透率增加相关. 向CDK1可能为侵袭性乳腺癌亚型提供新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物信息学是一种生物信息学.
背景情况:
- 循环素依赖激酶1 (CDK1) 对于细胞循环调节至关重要,但其在乳腺癌中的作用尚未完全理解.
- 描述CDK1的临床相关性和分子机制对于乳腺癌治疗至关重要.
研究的目的:
- 综合评估CDK1表达,预后价值和乳腺癌中的生物功能.
- 整合生物信息学和实验分析,以更深入地了解CDK1的作用.
主要方法:
- 分析了TCGA转录和临床数据,用于CDK1表达,诊断和生存.
- 使用TIMER和CIBERSORT进行免疫透和TMB分析.
- 在MDA-MB-231细胞中进行了功能实验 (shRNA淘汰,西部抹杀,CCK-8测定).
主要成果:
- 乳腺癌中CDK1表达升高,显示出高的诊断准确性 (AUC=0.978).
- 高的CDK1水平与攻击性亚型 (HER2,ER,PR阴性,基底类) 和较差的生存率相关.
- 通过降低AKT酸化和Cyclin D1,A和E1的表达,CDK1敲击抑制了增殖.
结论:
- CDK1是乳腺癌的致癌因子,促进瘤生长和免疫调节.
- 过度表达CDK1表明预后不佳,免疫透率增加,表明其作为诊断和治疗点的潜力.
- 向CDK1通路可能为侵袭性乳腺癌提供新的治疗策略,包括三阴性亚型.
相关概念视频
02:34Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
02:15M-Cdk Drives Transition Into Mitosis
6.2K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.2K
02:39Positive Regulator Molecules
6.4K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
6.4K
01:45Positive Regulator Molecules
133.9K
To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
133.9K
03:03mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
01:22PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K